Multiparametric Magnetic Resonance Imaging of the Prostate and Prostate-specific Membrane Positron Emission Tomography Prior to Prostate Biopsy (MP4 Study)

被引:4
|
作者
Woo, Henry H. [1 ,2 ,3 ]
Khanani, Hadia [2 ]
Thompson, Nadine J. [4 ]
Sorensen, Brian J. [4 ]
Baskaranathan, Sris [2 ,3 ]
Bergersen, Philip [2 ,3 ]
Chalasani, Venu [2 ,3 ]
Dean, Thomas [2 ,3 ]
Dias, Max [2 ,3 ]
Symons, James [1 ,2 ,3 ]
Wines, Michael [2 ,3 ]
Jain, Anika [2 ]
Nassour, Anthony -Joe [2 ]
Tarlinton, Lisa C. [2 ,4 ,5 ]
机构
[1] Australian Natl Univ, Coll Hlth & Med, Canberra, Australia
[2] Sydney Adventist Hosp, SAN Prostate Ctr Excellence, Sydney, NSW, Australia
[3] Sydney Adventist Hosp, Dept Urol, Sydney, NSW, Australia
[4] Sydney Adventist Hosp, SAN Radiol & Nucl Med, Sydney, NSW, Australia
[5] Sydney Adventist Hosp, SAN Radiol & Nucl Med, 185 Fox Rd, Wahroonga, NSW 2076, Australia
来源
关键词
Magnetic resonance imaging; Positron emission tomography; Prostate biopsy; Prostate cancer; Prostate -specific membrane; antigen; DIAGNOSTIC CERTAINTY; LEXICON;
D O I
10.1016/j.euros.2022.11.012
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Prostate-specific membrane antigen (PSMA) positron emission tomography/computerised tomography (PET/CT) is increasingly being utilised in the diagnostic pathway for prostate cancer (PCa). Recent publications have sug-gested that this might help identify those who can avoid biopsy.Objective: The primary objective of this study was to determine whether PET mag-netic resonance imaging (MRI) fusion could negate the need to biopsy prior to prostatectomy in a selected population of men.Design, setting, and participant: Multiparametric MRI (mpMRI) for PCa is our stan-dard of care prior to prostate biopsy. Biopsy-naive men with one or more Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesions >10 mm on mpMRI were invited to undergo PSMA PET/CT prior to biopsy. Following ethics approval, 60 men were recruited between September 2020 and March 2021. The key exclusion criteria included a previous history of PCa and previous prostate sur-gery or biopsy.Outcome measurements and statistical analysis: A positive PET MRI fusion scan was defined as "consistent with"as per the Memorial Sloan Kettering Cancer Center lexicon of certainty, and concordance with biopsy results was analysed. Clinically significant PCa (csPCa) was defined as grade group (GG) >= 2 on pathology. A chi-square analysis was performed with statistical significance defined at p < 0.05.Results and limitations: A total of 71 mpMRI lesions were positive on 61 (86%) PET MRI fusion scans. Fifty-nine of 61 lesions biopsied confirmed csPCa in 54 (92%). Of five of 59 lesions for which either biopsy was negative or low-grade cancer was found, three had rebiopsy of which two were confirmed to have csPCa corroborating with PET MRI fusion and one was reconfirmed to have GG1 only. For the remaining two, both had another lesion elsewhere in the gland confirming csPCa, and hence rebiopsy was not performed. Ultimately, 56 of 59 (95%) lesions with a positive PET MRI fusion scan were confirmed to have csPCa. All GG >3 can-cers had a positive PET MRI fusion scan. Conclusions: This prospective study of PET MRI fusion assessment of men with PI-RADS 4 or 5 lesion >10 mm on mpMRI confirms that the majority of men (95%) with a positive PET MRI fusion scan will have csPCa. This supports recently pub-lished retrospective data suggesting that selected men might avoid prostate biopsy prior to radical prostatectomy.Patient summary: In this research, we have confirmed that prostate-specific mem-brane antigen positron emission tomography/computerised tomography in combi-nation with magnetic resonance imaging could have an important role in enabling a diagnosis of prostate cancer. Using the combination of these scans, we could con-fidently predict the presence of aggressive prostate cancer in some men for which treatment is warranted. This means that there are some men who could possibility proceed directly to having prostate cancer surgery without the need for a confirma-tory prostate biopsy.(c) 2022 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creative-commons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:119 / 125
页数:7
相关论文
共 50 条
  • [21] Research progress on prostate-specific membrane antigen ligand positron emission tomography imaging of prostate cancer
    Li Y.
    Liu B.
    Yuan Y.
    Qin W.
    Shengwu Yixue Gongchengxue Zazhi/Journal of Biomedical Engineering, 2022, 39 (06): : 1263 - 1268
  • [22] Prostate-Specific Membrane Antigen Positron Emission Tomography and the New Algorithm for Patients With Prostate Cancer Prior to Prostatectomy
    Osborne, Joseph R.
    Bander, Neil H.
    Tagawa, Scott T.
    JAMA ONCOLOGY, 2021, 7 (11) : 1642 - 1643
  • [23] Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer
    Afaq, Asim
    Bomanji, Jamshed
    BRITISH MEDICAL BULLETIN, 2018, 128 (01) : 37 - 48
  • [24] The Sensitivity and Specificity of Multiparametric Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Predicting Seminal Vesicle Invasion in Clinically Significant Prostate Cancer: A Multicenter Retrospective Study
    Sitharthan, Darshan
    Kang, Song
    Treacy, Patrick-Julien
    Bird, Jacob
    Alexander, Kate
    Karunaratne, Sascha
    Leslie, Scott
    Chan, Lewis
    Steffens, Daniel
    Thanigasalam, Ruban
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (15)
  • [25] A comparison study of 68gallium-prostate-specific membrane antigen positron emission tomography-computed tomography and multiparametric magnetic resonance imaging for locoregional staging of prostate cancer
    Patel, Kartik Shashikant
    Singh, Tarun
    Raghuvanshi, Kshitij
    Sonar, Sameer
    Chaudhari, Rajeev
    UROLOGICAL SCIENCE, 2024, 35 (01) : 36 - 41
  • [26] Gallium 68 prostate-specific membrane antigen simultaneous positron emission tomography-magnetic resonance imaging: A novel approach in evaluation of carcinoma prostate
    Gambhir, A.
    Jena, A.
    Taneja, S.
    EUROPEAN JOURNAL OF CANCER, 2016, 54 : S36 - S36
  • [27] New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography
    Afaq, Asim
    Batura, Deepak
    Bomanji, Jamshed
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2017, 49 (05) : 803 - 810
  • [28] New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography
    Asim Afaq
    Deepak Batura
    Jamshed Bomanji
    International Urology and Nephrology, 2017, 49 : 803 - 810
  • [29] Single-fraction prostate-specific membrane antigen positron emission tomography- and multiparametric magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer local recurrences
    Ehret, Felix
    Hofmann, Theresa
    Fuerweger, Christoph
    Kufeld, Markus
    Staehler, Michael
    Muacevic, Alexander
    Haidenberger, Alfred
    BJU INTERNATIONAL, 2023, 131 (01) : 101 - 108
  • [30] Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: Promising novel option in prostate cancer imaging?
    Maurer, Tobias
    Beer, Ambros J.
    Wester, Hans-Juergen
    Kuebler, Hubert
    Schwaiger, Markus
    Eiber, Matthias
    INTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 (12) : 1286 - 1288